How Are Authorized Representative Responsibilities Divided for Overseas Registration of Rehabilitation Equipment?

When exporting rehabilitation equipment to overseas markets, the division of responsibilities for the Authorized Representative (or local agent) directly determines whether registration is smoothly approved and whether post-market compliance risks are managed. Enterprises should first assess whether the product falls within the target country's medical device regulatory scope, then determine the registration pathway and the responsible applicant entity according to risk classification. Rehabilitation equipment—including physical therapy devices, sports rehabilitation systems, walking aids, and electrical stimulators—may be classified as Class I, IIa/IIb, or higher risk in different jurisdictions. The Authorized Representative's core duties include submitting registration applications, receiving post-market surveillance notices, handling adverse event reports, supporting product changes and renewals, and serving as the primary point of contact for regulatory authorities. To avoid common pitfalls, manufacturers must clarify the representative's signing authority, certificate ownership, procedures for changes/renewals, and post-expiration arrangements for CE marking or other certificates. The recommended practice is to conduct a regulatory mapping analysis for the target country before starting the project, sign a clearly defined agency agreement, and prepare technical documentation, risk management files, clinical evidence, labels/instructions, and post-market surveillance procedures in advance. This reduces the burden of redundant documentation and deficiency responses in multi-country registrations. This article is compiled based on AIMEILI registration practice databases, international medical device registration knowledge, and public regulatory information; specific projects should be governed by the latest requirements of the target national regulatory authority and the product's documentation.

Applicable Scenarios and Core Issues

Overseas registration of rehabilitation equipment commonly requires the appointment of an Authorized Representative, but the definition and responsibilities of the representative vary significantly across countries and registration pathways. Manufacturers must first clarify the project scenario: Is it the first entry into the target market, or is an existing certificate being amended or renewed? Is the application initiated directly by the manufacturer or submitted through a local agent? Is the product a low-risk Class I device or a medium-to-high-risk device requiring clinical investigation? Each scenario leads to a different boundary of the representative's duties.

An Authorized Representative is not a mere intermediary or a contact person who only collects documents. In markets such as the European Union, the United Kingdom, and Saudi Arabia, the representative carries substantial obligations defined by law, including acting as the primary point of contact for regulatory authorities, maintaining technical files and providing them to review bodies upon request, reporting serious adverse events, and facilitating on-site inspections. In countries in Southeast Asia and Latin America, the local agent may focus more on license application and government liaison, but the same need for a clearly defined scope of authorization applies.

Rehabilitation equipment covers a wide range of products, including electric wheelchairs, therapy devices, rehabilitation training robots, walkers, orthoses, and pulsed magnetic therapy devices. These devices may be active or non-active, may contact the body for varying durations, and may have significantly different risk classifications, which directly affects the level of involvement expected from the Authorized Representative. If a manufacturer treats the arrangement as simply finding an agent for export, it may create a responsibility vacuum in registration documentation, quality system audits, and post-market surveillance.

Therefore, clarifying the applicable scenario is the first step in defining responsibilities. Enterprises should identify whether the target country is a member of the GHWP, whether MDSAP audit reports are accepted, whether a local Authorized Representative is mandatory, and what statutory role the representative plays in technical documentation and adverse event reporting.

Registration Decision Logic

To define the division of responsibilities for an Authorized Representative, a stepwise approach is recommended:

Step 1: Determine whether the product falls within the target country's medical device regulatory scope. In some countries, certain rehabilitation products may be classified as household appliances, fitness equipment, or assistive aids rather than medical devices. If a product is not a medical device, a local Authorized Representative is usually not required.

Step 2: Determine the product's risk class and registration pathway. For example, the U.S. FDA requires a product classification and a 510(k)/PMA pathway; the European Union employs MDR classification and Notified Body involvement; Saudi Arabia requires SFDA registration and a local Authorized Representative.

Step 3: Determine the applicant entity. A manufacturer may apply in its own name, or the local Authorized Representative may file as the applicant. In many countries, an overseas manufacturer must submit the application through a local Authorized Representative and act as the legal contact point. In such cases, the Authorized Representative appears as the certificate holder or the applicant company on the license.

Step 4: Assess the re-usability of existing documents. If the manufacturer has an NMPA registration certificate, CE technical files, an FDA 510(k), or an ISO 13485 certificate, these can serve as the basic technical documentation. However, the target country may require compliance with local standards, label language, test report formats, or even local testing. For example, some Latin American countries accept CE/FDA test reports but require a letter of authorization from the original laboratory and certified translations.

Finally, confirm the technical documentation, performance verification, risk management, clinical evaluation or clinical evidence, labels and instructions, local agent, Authorized Representative, and post-market maintenance requirements. The division of responsibilities for the Authorized Representative must be aligned with the product's risk class and registration pathway. High-risk rehabilitation devices may involve short-cycle clinical investigations, requiring the representative to assist with communication with clinical trial sites and ethics committees. Low-risk devices may only require documentary review, but the representative must still be capable of maintaining technical files and receiving regulatory notifications.

For GHWP member countries, multi-country registrations, Southeast Asia, the Middle East, and Latin America, the recommended strategy is to create one core technical file once and localize it for multiple countries. Manufacturers can build a master file based on the international STED structure, then supplement it with risk management reports, clinical evaluations, label and instruction translations, and submit it through the Authorized Representative in each jurisdiction. This approach reduces redundant work and ensures clear responsibility boundaries.

Documentation and Evidence

Documents relevant to the division of responsibilities of an Authorized Representative can be grouped into three categories: authorization documents, registration technical documents, and post-market surveillance documents.

Authorization documents include the power of attorney, agency agreement, and responsibility statement. These must clearly state the scope of authorization, validity period, signing authority, and renewal conditions.

Registration technical documents center on the product technical file, which typically includes product description, intended use, design principle, material specifications, manufacturing process, risk management report, performance verification report, clinical evaluation or clinical evidence, stability data, and sterilization validation (if applicable). If the rehabilitation device has software functions, software validation and cybersecurity information are also required.

Quality system evidence is indispensable. Manufacturers should provide the ISO 13485 certificate. If the target country accepts MDSAP audits, the MDSAP report may be used in place of part of the system audit. Under the EU MDR, an Authorized Representative must have access to the manufacturer's quality management system documents for inspection by authorities.

Labels and instructions for use are key review targets. Because rehabilitation equipment is often used by elderly individuals or persons with disabilities, the instructions must be clear and easy to understand, and warnings and contraindications must be accurately translated. The Authorized Representative is responsible for verifying that labels comply with target-country language and regulatory requirements, while the substantive responsibility remains with the manufacturer.

Post-market surveillance documents include adverse event reporting procedures, complaint handling records, periodic safety update reports, and corrective and preventive action (CAPA) records. The Authorized Representative must retain these records to provide to regulators upon request, and the manufacturer must update the representative with current information.

In addition, manufacturers should retain all communications with the Authorized Representative, application submission records, regulatory inquiries, and responses. These records demonstrate that the manufacturer has explicitly delegated certain responsibilities to the representative and serve as evidence for responsibility allocation in disputes.

Common Mistakes

• Treating the Authorized Representative as a mere courier that only submits documents, without defining in the contract its legal duties such as receiving regulatory notices, responding to deficiency letters, and participating in post-market surveillance.
• Failing to confirm who the certificate holder is. In many countries, the registration certificate displays a certificate holder or license applicant. If the holder's information is not clearly set, subsequent changes and renewals will encounter serious obstacles.
• Choosing an unsuitable Authorized Representative. Some agencies lack experience in rehabilitation equipment registration and may misjudge the risk classification, resulting in submission of documents that do not meet local technical review requirements.
• Neglecting the Authorized Representative's access to technical files. Regulators may require the representative to provide the full technical file within 30 days. If the manufacturer provides only a product parameter sheet rather than the complete file, this can lead to deficiencies or even withdrawal of registration.
• Not agreeing in the contract on certificate control and change procedures. When design changes, raw material changes, or label changes occur, failure to go through the representative for evaluation and submission of a change application may render the registration certificate invalid.
• Unclear post-market obligations. For example, who evaluates adverse events, who reports to the regulator, and who maintains records. Many contracts assign full responsibility to one party, making execution difficult.
• Using different Authorized Representatives for multiple countries but failing to harmonize document versions. Inconsistencies between technical documents and labels submitted in different countries make it difficult to track during deficiency resolution.
• Improper handling of renewal. If the Authorized Representative agreement expires and is not renewed or replaced in time, no one submits the renewal application before the deadline, and the certificate is officially cancelled.

Enterprise Preparation Checklist

• Complete a regulatory map for the target country, confirming whether the product is a medical device and its risk class and registration route.
• Compile an inventory of existing registration documents and system certificates, identifying which can be directly reused and which require additional tests or translations.
• Develop a master product technical file organized according to STED or target-country requirements, ensuring completeness and version control.
• Evaluate and select an Authorized Representative, requesting evidence of service scope, biocompatibility or electrical safety testing resources, and experience with similar products.
• Draft an agency agreement that clearly defines the representative's responsibilities, signing authority, fee structure, notification obligations, confidentiality, and post-termination certificate handling.
• Confirm the certificate holder information and determine with the representative the exact wording for the registration applicant and certificate holder.
• Prepare translated labels and instructions for use, have them reviewed by native speakers of the target language, and obtain the representative's confirmation of compliance with local regulations.
• Establish a post-market surveillance program, including complaint handling, adverse event reporting, annual updates, and information synchronization with the Authorized Representative.
• Archive all communication records and versions of technical files to preserve an evidence chain for regulatory audits or legal disputes.
• Define change and renewal management processes, specifying how quickly registration documents must be updated after design changes, system certification updates, or replacement of the Authorized Representative.

AIMEILI Perspective

The most common misconception about Authorized Representative responsibilities is that once an agent is appointed, everything is resolved. In reality, the manufacturer retains ultimate responsibility for the safety and effectiveness of a medical device after it is placed on the market. The Authorized Representative exists to help the manufacturer fulfill its regulatory interface obligations. For rehabilitation equipment, the end users are often patients with special needs or elderly people, and regulators scrutinize labels, instructions, and adverse event reporting with particular rigor. If the manufacturer treats the representative as a mere outsourcing provider for applications, a safety incident can quickly become a supply-chain breakdown and legal dispute.

What should be done early in the project? We recommend first performing a registration feasibility assessment that focuses on product classification, whether the target country mandates a local representative, and the rules for mutual recognition of test reports and data. Only then should the agency agreement be signed. Many manufacturers appoint an agent prematurely and discover that even the proposed risk classification is wrong, causing the cost of later deficiencies and retesting to far exceed expectations.

Which documents can be reused? NMPA registration files, CE technical documentation, FDA 510(k) submissions, ISO 13485 quality system files, and MDSAP audit reports can all serve as a foundation. However, risk management reports must be localized to address regional standards, clinical evaluation must consider local epidemiology or population differences, and labels and instructions must be translated. For example, alarm thresholds for a rehabilitation training robot or height and weight ranges in the labeling may differ from country to country and cannot simply be copied.

Why are the local agent, certificate control, and change/renewal procedures so important? Because the registration certificate is the entry permit for lawful sales in the country. If key fields such as certificate holder, Authorized Representative, or registered address are not properly controlled, the manufacturer will struggle when making changes, renewing, or responding to inspections. We have seen multiple cases where a manufacturer used an unreliable agent, the contract expired, the agent refused to cooperate with a change, and the certificate could not be transferred, forcing the manufacturer to start registration from scratch, wasting a year and significant costs.

How can manufacturers reduce the risk of redundant document preparation and deficiencies in multi-country registrations? The core is to establish a one master document, multi-country mapping mechanism. Build an English master document in STED format, then create a list of country-specific differences, such as standard versions, language requirements, and local test requirements, and supplement the files accordingly before submission through the respective Authorized Representatives. This approach avoids starting from the beginning in each country and helps the representative understand exactly which portion to review, reducing back-and-forth deficiencies.

Frequently Asked Questions

What is the difference between an Authorized Representative and a registration agent?

In many countries, the concepts of Authorized Representative and registration agent are interchangeable. However, under the EU MDR and the UKCA system, the Authorized Representative is given legal obligations, including representing the overseas manufacturer before regulators, maintaining technical files, and cooperating with market surveillance. A registration agent, in contrast, may be more focused on handling the licensing process and is not necessarily a statutory representative. Manufacturers should check the specific regulations of the target country to determine whether a legal role similar to an Authorized Representative exists.

If we change the Authorized Representative, does the existing registration certificate remain valid?

Usually, yes, but a change of Authorized Representative must be submitted to the regulatory authority, along with a power of attorney from the new representative. In the EU, when the Authorized Representative is changed, the new representative must provide a written declaration to the manufacturer and undertake obligations such as transferring documents. In many Latin American countries, changing the Authorized Representative requires the original representative's consent, so it is advisable to agree on the change process and handover duties in the agreement in advance.

Is the Authorized Representative liable for personal injury damages caused by product defects?

In most jurisdictions, the manufacturer bears ultimate product liability. The Authorized Representative may face administrative or civil liability only if it fails to fulfill its statutory duties, such as failing to report adverse events or failing to maintain technical files that would allow traceability. Manufacturers cannot shift all tort liability to the representative through contractual clauses, but the agency agreement should nevertheless include a clear mechanism for recourse and indemnification.

Continue Reading

• How Are Authorized Representative Responsibilities Divided for Overseas Registration of Imaging Equipment?
• How Are Authorized Representative Responsibilities Divided for Overseas Registration of Home Medical Devices?
• How Are Authorized Representative Responsibilities Divided for Overseas Registration of IVD Products?
• What Should Be Prepared Before Renewing the Overseas Registration of Patient Monitoring Equipment?
• Why Does the Overseas Registration Cycle For Implantable Products Extend?
• How Is Product Classification Determined for Overseas Registration of Dental Devices?

Return to FAQ Center.

Editorial Note and Scope of Application

Author: AIMEILI Regulatory Editorial Department

Professional Review: AIMEILI International Medical Device Registration Project Team

Source Principles: We prioritize official regulatory bodies, international organizations, standards organizations, and publicly available regulatory materials. Industry media and project experience are used only as secondary references.

Scope of Application: This article is intended for preliminary understanding, document preparation, and project planning. It does not replace the official requirements, testing conclusions, or legal advice of the target country's regulatory authority.

Published: 2026-08-21 10:41 | Updated: 2026-08-21 10:41